301060.SHE Shanghai Labway Clinical Laboratory Co Ltd
- Market cap
- CNY 4.07B
- P/E
- 101.5x
- P/B
- 2.61x
- ROE
- 6.1%
- Dividend yield
- 2.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301060.SHE undervalued?
Graham numberThe Graham number of Shanghai Labway Clinical Laboratory Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Labway Clinical Laboratory Co Ltd fundamental analysis
No fundamental analysis for Shanghai Labway Clinical Laboratory Co Ltd yet.
Shanghai Labway Clinical Laboratory Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, in-vitro diagnostic products, precision medicine, research and technical services, medical data management solutions and professional technical support services. In addition, the compa…
Full company profileShanghai Labway Clinical Laboratory Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Labway Clinical Laboratory Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 805M | 923M | 1.05B | 1.15B | 1.24B | 1.78B | 4.20B | 1.67B | 1.74B | 1.45B | 1.19B |
| Gross Profit | 270M | 275M | 321M | 347M | 395M | 673M | 1.78B | 329M | 333M | 347M | 295M |
| Operating Income | 81.1M | 7.14M | 107M | 131M | 178M | 319M | 949M | -136M | -69.3M | 29.6M | 57.8M |
| EBITDA | 107M | 28.0M | 164M | 177M | 206M | 367M | 977M | -95.6M | -32.2M | 96.2M | 135M |
| Net Income | 58.8M | 6.42M | 73.4M | 92.2M | 110M | 204M | 617M | -142M | -109M | -30.7M | 94.7M |
| EPS | 0.62 | 0.02 | 0.21 | 0.26 | 0.31 | 0.58 | 1.54 | -0.35 | -0.27 | -0.08 | 0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 944M | 1.33B | 1.44B | 1.40B | 1.47B | 2.11B | 3.75B | 2.99B | 2.62B | 2.29B | 2.10B |
| Total Liabilities | 329M | 226M | 262M | 186M | 224M | 466M | 1.47B | 1.01B | 803M | 647M | 478M |
| Shareholders' Equity | 579M | 1.08B | 1.15B | 1.18B | 1.22B | 1.56B | 2.06B | 1.78B | 1.66B | 1.55B | 1.56B |
| Cash & Short-term Investments | 240M | 140M | 205M | 485M | 533M | 773M | 666M | 861M | 829M | 759M | 816M |
| Total Debt | 75.3M | 70.0M | 30.0M | - | 68.5M | 65.7M | 212M | 349M | 247M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 27.1M | -95.5M | 185M | 70.6M | 168M | 224M | 84.2M | 547M | 216M | 269M | - |
| Capital Expenditure | 103M | 131M | 73.3M | 39.5M | 44.5M | 119M | 230M | 399M | 76.6M | 58.5M | 34.0M |
| Free Cash Flow | -76.1M | -226M | 111M | 31.1M | 123M | 105M | -146M | 148M | 140M | 210M | 291M |
| Ratios | |||||||||||
| ROE | 10.2% | 0.6% | 6.4% | 7.8% | 9.0% | 13.0% | 29.9% | -8.0% | -6.6% | -2.0% | 6.1% |
| ROA | 6.2% | 0.5% | 5.1% | 6.6% | 7.5% | 9.7% | 16.5% | -4.7% | -4.2% | -1.3% | 4.5% |
| Net Profit Margin | 7.3% | 0.7% | 7.0% | 8.0% | 8.9% | 11.5% | 14.7% | -8.5% | -6.3% | -2.1% | 8.0% |
| Debt to Equity | 0.13x | 0.06x | 0.03x | - | 0.06x | 0.04x | 0.10x | 0.20x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Labway Clinical Laboratory Co Ltd dividends
- Dividend yield
- 2.28%
- Forward dividend
- 0.18 CNY
- Payout ratio
- -
- Ex-dividend date
- Jun 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 92.7M | 0.23 | - |
| 2024 | CNY 7.36M | 0.02 | - |
| 2023 | CNY 137M | 0.34 | - |
| 2022 | CNY 126M | 0.31 | 20.3% |
| 2021 | CNY 302K | 0.00 | 0.1% |
| 2020 | CNY 35.2M | 0.10 | 31.9% |
| 2019 | CNY 64.4M | 0.18 | 69.8% |
| 2018 | 3.47M | 0.01 | 4.7% |
| 2017 | 27.8M | 0.08 | 433.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Labway Clinical Laboratory Co Ltd
- Insiders 59.74%
- Institutions 1.49%
- Public & others 38.77%
- Shares outstanding 401M
- Free float 165M
Shanghai Labway Clinical Laboratory Co Ltd company profile
- Company name
- Shanghai Labway Clinical Laboratory Co Ltd
- Ticker
- 301060.SHE
- ISIN
- CNE100004RG8
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,245
- Fiscal year end
- December
- Address
- Building 1, Lane 268, Shanghai, China, 200335
- Phone
- 86 40 0021 9090
- Website
- labway.cn
About Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, in-vitro diagnostic products, precision medicine, research and technical services, medical data management solutions and professional technical support services. In addition, the company offers leasing, business, and human resources services. The company serves medical and research institutes. Shanghai Labway Clinical Laboratory Co., Ltd. was founded in 1993 and is headquartered in Shanghai, China.
Shanghai Labway Clinical Laboratory Co Ltd management
6- Mr. Weixiong ZengChairman & GM · born 1968
- Ms. Haiyang WangHead of Finance Center & Director · born 1975
- Mr. Zhisen MaoDeputy General Manager · born 1960
- Mr. Guowei FangDeputy GM & Head of Medical Center · born 1956
- Jun HeAccounting Supervisor
- Ms. Crystal YangBoard Secretary · born 1989